Correction to: Endocrine (2024) https://doi.org/10.1007/s12020-024-04090-x, The article “Long-term safety and effectiveness of a somatropin biosimilar (Omnitrope®) in children requiring growth hormone therapy: analysis of final data of Italian patients enrolled in the PATRO children study”, written by Lorenzo Iughetti, Franco Antoniazzi, Claudia Giavoli, Simonetta Bellone, Tommaso Aversa, Laura Guazzarotti, Maria Elisabeth Street, Emanuele Miraglia del Giudice, Luca Persani, Gabriella Pozzobon, Letizia Ragusa, Stefano Stagi, Gianluca Tornese, Clara Zecchino, Chiara Mameli, Emiliano Zecchi, Paolo Fedeli, Markus Zabransky, Laura Lucaccioni and Stefano Zucchini, was originally published open access under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. As a result of the author’s/authors’ subsequent decision not to publish this article under the open access model, the copyright notice of the article was changed on 08 January 2025 to © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024 with all rights reserved. The original article has been corrected.
Correction to: Long-term safety and effectiveness of a somatropin biosimilar (Omnitrope®) in children requiring growth hormone therapy: analysis of final data of Italian patients enrolled in the PATRO children study (Endocrine, (2024), 87, 3, (933-942), 10.1007/s12020-024-04090-x) / Iughetti, L.; Antoniazzi, F.; Giavoli, C.; Bellone, S.; Aversa, T.; Guazzarotti, L.; Street, M. E.; Miraglia Del Giudice, E.; Persani, L.; Pozzobon, G.; Ragusa, L.; Stagi, S.; Tornese, G.; Zecchino, C.; Mameli, C.; Zecchi, E.; Fedeli, P.; Zabransky, M.; Lucaccioni, L.; Zucchini, S.. - In: ENDOCRINE. - ISSN 1559-0100. - 88:2(2025), pp. 668-669. [10.1007/s12020-025-04162-6]
Correction to: Long-term safety and effectiveness of a somatropin biosimilar (Omnitrope®) in children requiring growth hormone therapy: analysis of final data of Italian patients enrolled in the PATRO children study (Endocrine, (2024), 87, 3, (933-942), 10.1007/s12020-024-04090-x)
Street M. E.;
2025-01-01
Abstract
Correction to: Endocrine (2024) https://doi.org/10.1007/s12020-024-04090-x, The article “Long-term safety and effectiveness of a somatropin biosimilar (Omnitrope®) in children requiring growth hormone therapy: analysis of final data of Italian patients enrolled in the PATRO children study”, written by Lorenzo Iughetti, Franco Antoniazzi, Claudia Giavoli, Simonetta Bellone, Tommaso Aversa, Laura Guazzarotti, Maria Elisabeth Street, Emanuele Miraglia del Giudice, Luca Persani, Gabriella Pozzobon, Letizia Ragusa, Stefano Stagi, Gianluca Tornese, Clara Zecchino, Chiara Mameli, Emiliano Zecchi, Paolo Fedeli, Markus Zabransky, Laura Lucaccioni and Stefano Zucchini, was originally published open access under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License. As a result of the author’s/authors’ subsequent decision not to publish this article under the open access model, the copyright notice of the article was changed on 08 January 2025 to © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2024 with all rights reserved. The original article has been corrected.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
